Sonic Healthcare's Improving Results Meet a Surprise Swiss Funding Cut

A cheap valuation and improving FY26 results are offset by regulatory pressure in Australia and Germany, and a surprise Swiss funding cut driving FY27 downgrades.

28 Sep 2026 · 3 min read

Sonic Healthcare fell sharply after a disappointing FY25 result missed growth expectations, then a genuine profit warning driven by cost inflation and below-inflation Medicare reimbursements left the stock trading at a depressed valuation, with fund managers split between those who see genuine value and others worried the regulatory backdrop across Australia and Germany could squeeze margins further.

A disappointing result and reimbursement pressures depress the valuation

Infinity Asset Management, overweight, said the stock declined 8.4 percent across the month, with the pullback coming on the back of a sharp sell-off in August following the FY25 result, met with a negative market reaction as growth expectations were high, with SHL growing revenues 8 percent and net profit only 0.5 percent, a 7 percent miss to consensus, despite strength in the Australian, German and UK segments while anatomical pathology proved weaker. Oracle Advisory Group said it added Sonic only in April as an undervalued stalwart with modest growth expected, but the company had its own issues with cost inflation and below-inflation Medicare reimbursements, with the stock subsequently issuing a profit warning and now trading at a depressed valuation.

The results were met with a negative market reaction as growth expectations were high; despite this SHL grew revenues 8% and net profit grew 0.5% (7% miss to consensus). Despite strength in the Australian, Germany & UK segments, anatomical pathology weaker.

— Infinity Asset Management, Monthly Report, September 2025

A hold-versus-sell debate on regulatory risk

Alliance Bernstein, a hold but very interested, described a business that does blood tests, benefiting from the general view that prevention is better than cure, though also a get-cheap-or-go-home type business because governments want costs down, creating a conflict between revenue and volume. Paradice Investment Management, a sell, acknowledged the stock also looks cheap, but worried about the regulatory backdrop, especially for Australia and Germany, with a budget looming and concerns the government could extract further savings from the pathology sector, at the same time as facing high wage growth and cost imposts.

We worry about the regulatory backdrop, especially for Australia and Germany. So with a budget looming next week, we worry there are potentially further savings the government is looking to extract from the pathology sector. At the same time, you still have quite high wage growth and cost imposts coming through.

— Paradice Investment Management, Article, May 2026

A better FY26 result undercut by a Swiss funding cut

Pendal Group said Sonic Healthcare's FY26 result was one of its better ones in years, with revenue up 13 percent, though underlying organic growth was closer to 5 percent, but that momentum isn't carrying into FY27, with around 10 percent bottom-line downgrades driven by a surprise Swiss funding cut, a slow UK NHS contract ramp-up and harder than expected synergy capture in an inflationary environment. Investors Mutual Limited's Goode grouped Sonic alongside Healius as one of the two larger, lower-margin pathology peers whose comparative underperformance has fed market skepticism toward the sector, even as ACL has outperformed on margins.

Sonic Healthcare's FY26 result was one of its better ones in years, with revenue up 13%, though underlying organic growth was closer to 5%; that momentum isn't carrying into FY27, with ~10% bottom-line downgrades driven by a surprise Swiss funding cut, slow UK NHS contract ramp-up and harder-than-expected synergy capture in an inflationary environment.

— Pendal Group, Newsletter, August 2026

What fund managers say they are watching next is resolution of the surprise Swiss funding cut, progress of the slow UK NHS contract ramp-up, whether synergy capture improves in the inflationary environment, and how the Australian and German regulatory backdrop evolves given ongoing government pressure to reduce pathology sector costs.